Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/40369
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
Metadata
Show full item record
TREATMENT OPTIONS FOR AGE-RELATED MACULAR DEGENERATION: A BUDGET IMPACT ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM
Author
Affilliation
Fundação Oswaldo Cruz. Fiocruz Brasília. Brasília, DF, Brasil.
University of Brasilia, Brasília, DF, Brazil.
Federal University of São Paulo, São Paulo, SP, Brazil.
Federal University of Amazonas, Manaus, AM, Brazil.
Federal University of São Paulo, São Paulo, SP, Brazil.
University of Brasilia, Brasília, DF, Brazil.
Federal University of São Paulo, São Paulo, SP, Brazil.
Federal University of Amazonas, Manaus, AM, Brazil.
Federal University of São Paulo, São Paulo, SP, Brazil.
Abstract
Background Age-related macular degeneration (AMD) is a disease that causes reduced visual acuity and blindness. The new treatment options for AMD are not provided by the Brazilian public health system. Objective To conduct a budget impact analysis of three scenarios for the introduction of AMD treatments: all the medications (verteporfin, ranibizumab, and bevacizumab–the reference scenario), ranibizumab alone, and bevacizumab alone. Methods The basic assumption was that the Brazilian public health system would treat the entire target population with AMD aged > 70 years between 2008 and 2011. The size of the population of interest was estimated from official population projections and the prevalence of the disease was obtained from a systematic review. Medication prices were estimated by weighting their market values with correction factors to take account of the public procurement policy. The possibility of aliquoting bevacizumab was also considered. A panel of experts was consulted to estimate the market share of the different medications for the reference scenario. The incremental costs of the ranibizumab-alone and bevacizumab-alone scenarios compared to the reference scenario were calculated. Univariate sensitivity analyses were run to check the robustness of the model. Results In four years, the Brazilian public health system would have treated 1,136,349 individuals with AMD. The annual costs of treating one patient would have been US$476.65 for bevacizumab, US$11,469.39 for ranibizumab, and US$4,376.28 for verteporfin. The incremental cost of the ranibizumab-alone scenario would have been US$1,878,318,056.00 in four years, while the incremental cost for the bevacizumab-alone scenario would have been a reduction of US$4,978,326,359.00 (i.e., a cost saving) in the same period. The bevacizumab-alone option was found to represent a cost saving across sensitivity analyses. Conclusion The introduction of bevacizumab for the treatment of AMD is recommended for the Brazilian Public Health System.
Share